Evidence map›Paper›PMID 38222097›Full record

ArticleGlobal heart2024

The Burden of Chagas Disease in the Contemporary World: The RAISE Study.

Antonio Luiz Pinho Ribeiro, RAISE Study Collaborators, Ísis Machado, Ewerton Cousin, Pablo Perel, Caroline Demacq, Yvonne Geissbühler, Aline de Souza, Alvaro Sosa Liprandi, Bruno R Nascimento and 12 more

Open access · goldAbstract read
In one paragraph

Article in Global heart, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Chagas disease: host responses, parasite evasion and vaccine advances.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026
    Review
  5. Primary care and community-based screening for Chagas disease in London, United Kingdom, August 2023 to January 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Observational
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Pathogens (Basel, Switzerland) · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Frontiers in microbiology · 2024
    Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 6 countries.

Antonio Luiz Pinho RibeiroHospital das Clínicas da Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 110 -Santa Efigênia, Belo Horizonte -MG, 30130-100, BR.
RAISE Study Collaborators
Ísis MachadoDepartment of Family Medicine, Mental and Collective Health, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
Ewerton CousinInstitute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, United States of America.
Pablo PerelWorld Heart Federation, Geneva, Switzerland.
Caroline DemacqGlobal Health, Novartis Pharma AG, Basel, Switzerland.
Yvonne GeissbühlerGlobal Health, Novartis Pharma AG, Basel, Switzerland.
Aline de SouzaDepartment of Economics, Faculty of Economic Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Alvaro Sosa LiprandiCardiology Department, Sanatoria Guemes, Buenos Aires, Argentina.
Bruno R NascimentoHospital das Clínicas da Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 110 -Santa Efigênia, Belo Horizonte -MG, 30130-100, BR.
Elisabeth F FrançaPostgraduate Program in Public Health, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Francisco Rogerlândio Martins-MeloInstituto Federal de Educação, Ciência e Tecnologia do Ceará - Campus Fortaleza, Fortaleza, Brazil.
Gregory A RothInstitute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, United States of America.
Israel MolinaInternational Health Unit Vall d'Hebron-Drassanes, Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Kenya NoronhaDepartment of Economics, Faculty of Economic Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Lenice IshitaniEpidemiological Surveillance Division, Belo Horizonte Municipal Health Department Belo Horizonte, Brazil.
Mariângela CarneiroDepartment of Parasitology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Monica QuijanoGlobal Health, Novartis Pharma AG, Basel, Switzerland.
Monica V AndradeDepartment of Economics, Faculty of Economic Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Mohsen NaghaviInstitute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, United States of America.
Jonathan F MosserInstitute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, United States of America.
Daniel J PiñeiroWorld Heart Federation, Geneva, Switzerland.
Universidade Federal de Minas Gerais · BRHospital das Clínicas da Universidade Federal de Minas Gerais · BRInstitute for Health Metrics and Evaluation · USNovartis (Switzerland) · CHUniversity of Washington · USHelios Salud · ARInstituto Federal de Educação, Ciência e Tecnologia do Ceará · BRPrefeitura Municipal de Belo Horizonte · BRUniversidade Federal de Ouro Preto · BRVall d'Hebron Hospital Universitari · ESWorld Heart Federation · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease (ChD), a Neglected Tropical Disease, has witnessed a transformative epidemiological landscape characterized by a trend of reduction in prevalence, shifting modes of transmission, urbanization, and globalization. Historically a vector-borne disease in rural areas of Latin America, effective control measures have reduced the incidence in many countries, leading to a demographic shift where most affected individuals are now adults. However, challenges persist in regions like the Gran Chaco, and emerging oral transmission in the Amazon basin adds complexity. Urbanization and migration from rural to urban areas and to non-endemic countries, especially in Europe and the US, have redefined the disease's reach. These changing patterns contribute to uncertainties in estimating ChD prevalence, exacerbated by the lack of recent data, scarcity of surveys, and reliance on outdated models. Besides, ChD's lifelong natural history, marked by acute and chronic phases, introduces complexities in diagnosis, particularly in non-endemic regions where healthcare provider awareness is low. The temporal dissociation of infection and clinical manifestations, coupled with underreporting, has rendered ChD invisible in health statistics. Deaths attributed to ChD cardiomyopathy often go unrecognized, camouflaged under alternative causes. Understanding these challenges, the RAISE project aims to reassess the burden of ChD and ChD cardiomyopathy. The project is a collaborative effort of the World Heart Federation, Novartis Global Health, the University of Washington's Institute for Health Metrics and Evaluation, and a team of specialists coordinated by Brazil's Federal University of Minas Gerais. Employing a multidimensional strategy, the project seeks to refine estimates of ChD-related deaths, conduct systematic reviews on seroprevalence and prevalence of clinical forms, enhance existing modeling frameworks, and calculate the global economic burden, considering healthcare expenditures and service access. The RAISE project aspires to bridge knowledge gaps, raise awareness, and inform evidence-based health policies and research initiatives, positioning ChD prominently on the global health agenda.

Indexed as

Chagas CardiomyopathyChagas DiseaseAdultHumansLatin AmericaPrevalenceSeroepidemiologic StudiesBurden of diseaseChagas cardiomyopathyChagas diseaseEpidemiology

Identifiers

PMID38222097
PMCPMC10785959
OpenAlexW4390664139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.